Evaluation of interventions designed to increase diagnosis and treatment of patients with hepatitis C virus infection in primary care and drug treatment settings (HEPCATT).
| INTRODUCTION
The previous standard of care, involving complex, poorly tolerated and long periods of treatment with ribavirin and pegylated interferon, provided a challenge to optimal treatment initiation and retention in care. Improvements to care and health outcomes are, however, expected through the introduction of the new direct acting antiviral (DAA) treatments, which are more efficacious, of shorter treatment duration and have a better side effect profile than the previous treatment options. The timely use of the DAAs is expected to lead to individual health benefits and to a reduction in the pool of infectious people, who are the source of onward transmission. Several modelling studies have shown that increased HCV treatment among PWID will reduce prevalence and onward transmission, [4] [5] [6] [7] [8] especially when combined with opioid substitution therapy and high coverage of needle and syringe programmes. 7 Modelling predicts that rapid scale up of HCV treatment in those with moderate-to-severe liver disease will curtail morbidity and mortality from end-stage liver disease, 9,10 but to make a substantial impact on transmission, treatment of mild disease is also required. 11 In the era of the new DAAs, it is important therefore to have a baseline measure of the previous standard of care against which to assess the impact of treatment strategies with DAAs and highlight where gaps in the patient pathway persist. 
| Treatment algorithm
Evidence of treatment was derived using an algorithm where four or more sequential HCV-RNA test results within a 390-day period of an initial positive RNA result was considered suggestive of monitoring during treatment with the standard of care (ribavirin and pegylated interferon-based regimens). 15 Persons with a final negative HCV-RNA test result within the 390-day period were considered to have responded to therapy, and to have achieved a sustained virological response (SVR). 16 The algorithm was validated using a clinical cohort database in Nottingham, and the algorithm results were found to have high sensitivity, specificity, PPV, NVP and inter-rater agreement.
Treatment uptake was estimated for all persons with a positive HCV-RNA regardless of when the test was conducted following a positive anti-HCV result. Among those for whom there was evidence of treatment initiation, the proportion with SVR was estimated.
| Statistical analysis
The cascade of care among those newly testing positive for anti-HCV was examined using descriptive analysis. Proportions were compared using the χ 2 test. Three multivariable models identified factors associated with having an RNA test following a positive anti-HCV test result, initiating treatment following a positive RNA result, and achieving SVR following treatment initiation, adjusting for year of diagnosis, age, sex, region and setting of diagnosis. An interaction between region and speciality of test was found to be significant (P < .001) for both variables, and thus, we re-categorized these two variables to cre- 13 678 of these patients were excluded from further analysis as there was an RNA test reported to SSBBV prior to the first anti-HCV result. T (Table 2C) . 
| RESULTS

Of
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T A B L E 1 (Continued)
T A B L E 2 Results from logistic regression analysis to identify factors associated with A. having an RNA test following a positive anti-HCV result, B. evidence of treatment among persons with a current infection (RNA positive) and C. 
| DISCUSSION
Our analysis demonstrates that in the pre-DAA era, confirmation of a current HCV infection occurred in 77% of persons positive for anti-HCV, with a low uptake of treatment of 11.9%, and attainment of SVR 5.9% overall. If restricting the cascade to those who were RNA positive following an anti-HCV-positive result, around a fifth had evidence of treatment and half of those were estimated to have been cured.
Confirmation of current infection (viraemia) following a positive
anti-HCV result is a critical first step in the cascade that triggers referral for and consideration of treatment. Among our population, 65%
of patients had had a test where the timing of the RNA test suggested that the same sample as for anti-HCV testing was used. Alternative pathways result in the antibody and RNA tests being conducted on separate samples requiring patients to re-attend for a blood test, increasing the likelihood of loss to follow up. To counter this, NICE recommend that RNA testing be conducted on the same sample, referred to as "reflex testing"; 17 this approach has been shown to reduce referral and testing costs, with a faster treatment initiation following a reflex test. 
In our data, the lower rates of treatment in recent years com- This study provides important cascade estimates to benchmark progress towards elimination of HCV as a major public health threat, providing a baseline cascade of care for the pre-DAA period.
These data will enable persistent barriers to be identified, as well as inequities in performance across geographical regions. The cascade of care contributes to the evaluation of clinical and public health HCV control strategies, which may inform the allocation of resource for health service planning. Furthermore, understanding and addressing patient and structural factors that influence engagement in the patient care pathway will impact the overall goal to reduce HCV transmission and HCV-associated cirrhosis, cancer and death. Collective and concerted efforts are needed to improve the cascade of care for HCV within England and to realize the population benefits from prevention and treatment interventions.
